Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD. by Croft, Simon L
Croft, SL (2017) Leishmania and other intracellular pathogens: selec-
tivity, drug distribution and PK-PD. Parasitology. pp. 1-11. ISSN
0031-1820 DOI: https://doi.org/10.1017/S0031182017001664
Downloaded from: http://researchonline.lshtm.ac.uk/4503962/
DOI: 10.1017/S0031182017001664
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
 Leishmania and other intracellular pathogens: selectivity, drug distribution and PK PD  
 
[BSP Autumn Symposium “Microbial protein targets: towards understanding and 
intervention”, 14th – 16th September 2016, University of Durham UK] 
 
 
Simon L. Croft 
 
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine  
 
 
Corresponding author:  Simon L. Croft, Faculty of Infectious and Tropical Diseases, London 
School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK; email: 
simon.croft@lshtm.ac.uk 
 
 
 
Abstract 
New drugs and treatments for diseases caused by intracellular pathogens, such as 
leishmaniasis and the Leishmania species, have proved to be some of the most difficult to 
discover and develop. The focus of discovery research has been on the identification of 
potent and selective compounds that inhibit target enzymes (or other essential molecules) 
or are active against the causative pathogen in phenotypic in vitro assays. Although these 
discovery paradigms remain an essential part of the early stages of the drug R & D pathway, 
over the past two decades additional emphasis has been given to the challenges needed to 
ensure that the potential anti-infective drugs distribute to infected tissues, reach the target 
pathogen within the host cell and exert the appropriate pharmacodynamic effect at these 
sites. This review will focus on how these challenges are being met in relation to Leishmania 
and the leishmaniasis with lessons learned from drug R & D for other intracellular 
pathogens.  
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Introduction 
In 2017 a small collection of drugs and treatments are used and recommended for visceral 
leishmaniasis (VL) (WHO, 2010; Aronson et al., 2016) and even fewer that have proven 
effective in the treatment of cutaneous leishmaniasis (CL) (Gonzalez et al. 2008, 2009; 
Aronson et al. 2016). Of these, and still widely in use, are the pentavalent antimonials 
(Pentostam has been in use since the 1940s; Goodwin, 1995), amphotericin B which was 
first used for leishmaniasis in 1960 (Sampaio et al.,196o) and as a liposomal formulation in 
1991 (Davidson et al 1991), paromomycin first used for leishmaniasis in 1963 (Kellina, 1966), 
and miltefosine identified as anti-leishmanial in 1984 (Croft et al. 1987) and registered for 
use for VL treatment in 2002 (Sundar et al. 2012). The limitations of these drugs and 
treatments have been reviewed elsewhere (Croft, Olliaro, 2011; Aronson et al. 2016). It is 
worth noting that these drugs providing the standard treatments for VL and CL are mainly 
re-purposed. To help improve the drug R & D process it is important to ask why it is taking 
so long to identify purpose-designed anti-leishmanials.  
Approaches to the design, discovery and development of anti-infectives have advanced 
considerably over the past two decades and several unique molecular and biochemical 
targets of parasites/microbes are the subject of other articles in this volume [Editor to 
include REFS]. For leishmaniasis advances in molecular biology and structural biology have 
similarly led the elaboration of validated targets and inhibitors (Gilbert, 2013; Horn and 
Duraisingh, 2014), whilst high-throughput (HTS) and high content (HCS) have led to the 
identification of novel chemical series (Siquiera-Neto et al. 2012; Pena et al. 2015), as well 
as the identification of novel targets (Khare et al. 2016). A pragmatic use of screening and 
extension of chemical series with known anti-kinetoplastid activity has produced lead 
compounds, and novel chemical entities (NCEs), from oxaboroles, nitroimidazoles, 
aminopyrazoles; which are all promising candidates in the anti-leishmanial development 
pipeline (www.dndi.org).  
The parts played by pharmacokinetics and medicinal chemistry have also lead to improved 
design of compounds able to target pathogens in infected tissues, for example in the CNS 
(Wring et al. 2014) and the macrophage (Rajendran et al. 2010), tissues that are relevant to 
the distribution of anti-trypanosomal and anti-leishmanial agents. In addition, the past 
decade has seen the integration of pharmacokinetics (PK), pharmacodynamics (PD) and 
physiology-based (PB) modelling, as illustrated in recent reviews on PK PD analysis (Nielsen 
and Friberg, 2013) and PB PK analysis (Edginton et al.  2006), into drug design and the 
prediction of appropriate dosing of novel and current anti-infective drugs. The importance 
of PK PD analysis has been well demonstrated for drug design for Mycobacterium 
tuberculosis (Davies and Nuermberger, 2008; Dartois, 2014), a pathogen that occupys a 
similar intracellular site as Leishmania.  Another recent approach, using small molecules, has 
been to target host factors/receptors and nutrient sources, as considered for 
Mycobacterium tuberculosis (Zumla et al. 2014; Guler and Brombacher, 2015), and in a more 
limited way for leishmaniasis, for example with simvastatin (Parihar et al. 2016). Modulation 
of the host’s  immune response has been a longer term goal, with some small molecules 
showing activity through known targets, for example, imiquimod (Buates et al. 1999) and 
tucaresol (Smith et al. 2000).  
 
Leishmania, physiological barriers and drug distribution  
There is nothing new about the concept of selectivity and drug distribution as the basis for 
the design, discovery and development of anti-infective drugs. Over the past century our 
work has been framed by the likes of Paul Ehrlich (1913), “…we may speak of magic bullets 
which aim exclusively at the dangerous intruding parasites, strangers to the organism, but 
do not touch the organism, itself and its cells…”. Adrien Alberts (1985) also described the 
challenges of achieving drug selective toxicity, comparing them at three levels – whole body 
distribution, biochemistry and cytology, while linking the physicochemical properties of 
compounds/drugs to pharmacodynamic effects.   
At the start of the drug discovery process it is essential to consider both (i) the target 
product profile (TPP) of the drug needed (see for example, www.dndi.org/diseases-
projects/target-product-profiles) and (ii) the required distribution and pharmacokinetics of 
novel compounds to infected tissues. These considerations have to be integrated into the 
discovery and development of new treatments for both VL and CL. The design of oral drugs 
or topical formulations for the treatment of VL and/or CL has to account for the number of 
physiological barriers that the anti-leishmanial molecule meets before reaching the  
molecular target. Both the series of membrane barriers and the different protein binding 
properties in plasma and tissues (Figure 1), are challenges to be met before the novel 
compound reaches the macrophage host cell in which the Leishmania amastigote survives 
and multiplies (Figure 2). For CL drugs, there are the additional barriers of extravasation and 
the interstitial fluid compartment, factors often not considered in this complex design. 
These challenges are not exclusive to those working on drug R & D for Leishmania; similar 
problems arise for intracellular bacteria, in particular Mycobacteria, and we can learn much 
from that research (Dartois, 2014).  
So, how can our knowledge of tissue and cellular distribution be exploited to improve drug 
design ? How can our understanding of membrane barriers and protein binding improve our 
ability to ensure drugs reach the sites where they are needed ? How can formulations and 
drug delivery be best exploited for this purpose ?  
 
Selectivity and Pharmacodynamics 
The initial identification of hit and lead compounds is normally determined in in vitro assays. 
Criteria for in vitro assays to measure killing of the intracellular Leishmania amastigote, were 
listed several decades ago (Croft. 1986); this list needs to be updated to include (i) the rate 
of kill, which has been shown to be important for other protozoa (Sanz et al., 2012), (ii) the 
type of macrophage used (see Seifert et al. 2010 below), and (iii) a panel of recent clinical 
isolates, as there is known strain/species variation in drug sensitivity (Croft et al. 2006).  The 
standard phrase to introduce the Leishmania parasite in many reviews is “Leishmania 
survive and multiply in host macrophages”. Leaving aside immunological issues of 
macrophage activation (Kaye and Scott.  2011), measurements of drug or NCE effects should 
relate to potency against a dividing population of amastigotes in a defined macrophage 
population.  However, there are four possible states for an amastigote in the macrophage 
(Figure 3): stasis, division, death, or escape.  These issues, are also a major concern for M. 
tuberculosis researchers, but have only recently been investigated for Leishmania.  In vitro 
studies have given some measures of rate of division through 3H-thymidine uptake (Sifontes 
and Croft, unpublished) and the bromodeoxyuridine analogue (EDU) (Tegazinni et al. 2016), 
both methods indicating incorporation these indicator of nucleic acid synthesis into about 
50% of L. donovani amastigotes in macrophage assays. In the steps from in vitro assay to 
rodent model and from rodent model to human, it is essential to know the “predictivity” of 
the model. So, are in vitro assays with rapid rates of division more predictive of activity in 
the rodent model than those with slow rates of division?  Some in vivo studies suggest that 
the answer is possibly not.  Recent studies on L. major and L. mexicana amastigotes in 
mouse models have shown that (i) L. mexicana amastigote division rate is slow (12 days) and 
sub-populations develop that are either semi-quiescent or fast-growing state (Kloehn et al. 
2015), and (ii) L. major amastigotes in lesions similarly show fast and slow replicating populations 
(Mandell and Beverley, 2017).  Similar questions must now be asked about L. donovani liver and 
spleen infections in mouse and hamster models to understand the relevance and predictivity 
of our current models.  This underlines the frailty of the PD parameters currently applied in 
PK PD analysis for Leishmania models. It would be a great benefit to Leishmania research to 
be able to tranfect with reporter genes that reflect in vivo growth rates. In studies on 
Salmonella different bacteria cell division rates in different tissues were shown to correlate 
with different levels of killing by antibiotics (Claudi et al. 2014).  
In addition to the above concerns about “predictivity”, most amastigote-macrophage in 
vitro assays, the current workhorse of anti-leishmanial drug discovery, over the past three 
decades, have used either macrophage cell lines (eg THP-1 cells) or primary isolated rodent 
macrophages (De Rycker et al. 2013; Neal and Croft, 1984).  These have on the whole have 
been useful in hit and lead identification. Whether there are more appropriate assays for 
further evaluation and lead identification has been questioned. Ex vivo models with splenic 
and lymph node tissue have been used in drug assays (Osorio et al. 2011; Peniche et al. 
2014) to try to more closely match host physiological conditions. Recently we have 
developed a medium perfusion/flow system, using interstitial flow rates, with L. major 
infected macrophages. This a shift in the dose response curves of several standard anti-
leishmanial drugs in flow vs. static systems (O’Keeffe, Croft, unpublished), where EC50 points 
were similar but EC90 points were significantly lower in the flow model.  
 
Macrophages 
The host macrophage is a central consideration in drug design and targeting in addition to 
it’s role in vitro drug assays, from monocytic cell lines (such as THP-1, J774 lines) used in 
HTS, to murine peritoneal or bone marrow macrophages used in evaluation and mechanistic 
studies.  The role of the macrophage in the immune response, pathogenesis, and parasite 
invasion and survival in the phagosomal compartment has been well described elsewhere 
(Kaye and Scott, 2011). One “macrophage” factor that is important in therapy and certainly 
in deriving PD parameters, is the heterogeneity of the macrophage cell population (Gordon 
et al. 2014) with different cell types having different functions and properties in different 
tissues.  Recent in vitro studies with L. donovani in amastigote macrophage assays has 
shown that significant differences in amastigote drug susceptibility are macrophage-type 
dependent (Seifert et al. 2010; Konouridou et al. 2017). This is not just an issue for 
standardisation of assays, it is also important in understanding differences in host cell drug 
accumulation and role of transporters, as well as drug metabolism, for example pentavalent 
antimonials are metabolised by macrophages (Frezard et al. 2009) and their activity altered 
through macrophage activation (Murray et al. 1988). The changes in macrophage 
metabolism with Leishmania infection could also impact drug activity and be different 
between macrophage populations, as has been shown for M. tuberculosis using RNA-seq 
analysis (Andreu et al., 2017).  Connections between drug uptake to cell type, infection, and 
activation status have long been defined for antibacterials (Carlier et al. 1990). With new 
sensitive methods to measure anti-leishmanial drug accumulation into immune cells (Kip et 
al. 2015) further studies to define Leishmania – host cell – drug interactions are needed. 
There is also opportunity to exploit the physicochemical properties of the phagolysosomal 
compartment, by manipulating conditions to improve drug activity, as exemplified by 
doxycline treatment of Coxiella infection (Maurin et al. 1992). The relationship between the 
pH of the phagolysosomal vacuole and amastigote survival is well established and pH 
manipulation with basic drugs, such as chloroquine, leads to parasite death. We have 
recently shown that in combination with chloroquine the activity of paromomycin can be 
significantly enhanced against L. major and L. mexicana amastigotes in vitro in mouse 
peritoneal macrophages (Wijnant et al. 2017a).  The acidic environment of the lysosomal 
compartment of cells has been studied in relation to the accumulation of charged basic 
molecules, with dicationic molecules such as azithromycin having high accumulation levels 
(see Bambeke et al. 2006). The potential of for concentration and trapping through 
protonation of novel molecules was exquisitely exploited by Rabinovitch et al (1986) using 
amino acid esters to kill L. amazonensis amastigotes in mouse peritoneal macrophages.  
Regulation of the phagosome compartment occurs through a number of membrane 
enzymes and transporters, including the well-characterised vacuolar proton-ATPase (v-
ATPase) involved in vacuole acidification and biogenesis (Vinet et al. 2011) and the cation 
transporter Nramp 1 (Jabado et al. 2000). Vacuolar enzyme and pH manipulation is being 
exploited in anti-cancer therapies, where the actions of known inhibitors synergize with 
standard drugs, with an impact on chemosensitization and reversal of chemoresistance 
(Swietach et al., 2012). This is an area little studied in relation to Leishmania ; one report has 
shown naloxonazine can upregulate V-ATPase in L. donovani infected THP-1 cells (De 
Muylder et al., 2016). Outside the phagolysomal vacuole, the metabolic changes seen in 
macrophage biology and the numerous pathways altered by Leishmania infection, from iron 
to cholesterol and beyond, has been recently reviewed (Duque and Descoteaux, 2015). 
Finally, the macrophage cell surface has several defined receptors that have been used in 
drug targeting to these host cells. 25 years ago Negre et al. (1992), showed that allopurinol 
riboside linked to mannosylated - poly-L-lysine as the carrier molecule to target the mannose 
receptor, improved drug activity 50-fold in an in vitro macrophage model. There have been 
several other publications describing tagged liposomes or nanoparticles in experimental 
models to target and increase drug accumulation by infected macrophages. However, given 
the added complexity of the synthesis, costs, stability and pharmacokinetics, it is unlikely 
that this approach will lead to new treatments for leishmaniasis.  
 
Pharmacokinetics and Predictive models 
As part of the effort to reduce the attrition rates that occur at each stage of the drug R & D 
process - from in vitro to animal models, from animal models to clinical candidate, and then 
in clinical trials - major efforts have been made to develop more predictive models to 
advance optimised novel compounds at each stage (for pharmacodynamics see above) and 
their behaviour in animal models and humans i.e., pharmacokinetics. PKs normally 
encompass the properties of a novel compound/drug of absorption, distribution, 
metabolism, and excretion. The anti-infective drug researcher also needs to ensure 
appropriate distribution of the compound to the infected tissue in the host, as well as 
retention of the compound within the infected tissue /cells for a period to give sufficient 
exposure to significantly reduce the parasite load. Over the past two decades there has 
been an increasing focus on the interrelationship between PDs and PKs, including tissues 
other than just plasma in the analysis. The PK PD paradigms were first outlined for anti-
bacterials (Craig, 1998) with an initial focus on how this information, which often focuses on 
defining drug activities in terms of either concentration dependent rate of killing or time 
dependent rate of killing, can be used to help determine effective dose regimens. For anti-
leishmanials PK PD analysis has helped to re-define miltefosine dosing in children for both 
VL and CL (Dorlo et al. 2012; Castro et al. 2017). However, for most anti-leishmanial drugs 
we have little data on their time-dependent or concentration-dependent activities, nor how 
this data can be used to optimise dose regimes. Analytical and mathematical tools are 
available to simulate PK/PD relationships of anti-leishmanials when there is sufficient and 
appropriate data. One such system has been developed for anti-malarial pre-clinical 
development, which has helped to identify the properties of compounds important for 
clinical performance and, importantly, partner drugs for combination therapy (Patel et al. 
2013; Alijayyoussi et al. 2016).  
This analysis of the PK PD relationship has also become central to drug development. A 
Pfizer team analysed the role of fundamental PK PD as part of a process to improve the 
survival rate of compounds in clinical trials i.e., what predictive indicators are of most 
importance to reduce attrition. They defined “three pillars of survival” for a novel 
compound as (i) exposure at the target site of action over a desired period of time, (ii) 
binding to the pharmacological target as expected for its mode of action, and (iii) expression 
of pharmacological activity commensurate with the demonstrated target exposure and 
target binding (Morgan et al. 2012).  An important element of PK PD analysis is that in vivo 
only the free (i.e. not bound to protein) drug concentration determines activity (Smith and 
Kerns, 2010); hence for Leishmania knowledge of drug concentration in the phagosome 
vacuole is of importance but so far undetermined. For leishmaniasis, we have limited 
retrospective data on miltefosine, as summarised by Dorlo et al. (2012). More research has 
been reported on the liposomal formulation of amphotericin B, the unilamellar liposome 
AmBisome ™.  We have shown that in a BALB/c mouse model (with data from liver, spleen, 
and plasma) that following iv dosing of AmBisome parasites in the liver are killed quicker 
and more effectively in those in the spleen (Voak et al. 2017). This can be explained by more 
extensive drug accumulation by the liver than spleen and the different drug kinetics 
between the two organs, although drug accumulation in these target organs was higher 
during the early stages of infection than later stages. Earlier studies with AmBisome in mice 
showed lower amphotericin B accumulation in infected than uninfected mice and also that 
the formulation was less effective in later stage than early stage infection (Gerskovich et al., 
2010; Mullen et al. ,1998).  The effectiveness of drugs in different tissues and distribution of 
drug in the tissues needs to be considered alongside the changes that occur in liver and 
spleen structure and function during early and late stages on infection (Yurdakul et al., 
2011; Kaye and Beattie, 2016).  Recent studies on M. tuberculosis drugs to study their 
spatial distribution in lung lesions used MALDI mass spectrometry imaging to reveal which 
TB drugs penetrated the lesions (Prideaux et al, 2015); this is an approach which should be 
applied to help us understand the tissue distribution of anti-leishmanials.  
 
The use of transfected Leishmania parasites with either fluorescent or bioluminescent 
properties have been used in studies on infection, pathology and chemotherapy over the 
past decade. But in terms of analysing key properties of anti-leishmanial drug action, these 
methods are only now starting to be fully exploited, in particular in rodent models of several 
species causing cutaneous leishmaniasis where drug efficacy and relapse have been 
measured (Caridha et al. 2017; Coelho et al. 2016). However, with good signal and high 
resolution imaging it will be important to improve the methodologies to measure (i) dose 
response effect, (ii) in vivo rate of kill and (iii) any differences in drug efficacy between sites 
of infection.   
Drug combinations, which are present co-administrations for leishmaniasis really co-
administrations, have proved to be clinically advantageous in the treatment of VL (Sundar et 
al., 2011). Current combinations of standard anti-leishmanial drugs are based solely on 
doses used in monotherapies. As novel oral compounds are developed over the next 5 years 
and genuine combinations are discussed, then drug combinations based upon knowledge of 
PK PD components of partner drugs and their interactions will be needed, as shown for 
antimalarials (Hastings and Hodel, 2016).  We also know that major challenges for treatment 
are VL – HIV co-infections (van Griensven et al. 2014). There have been some in vitro studies 
on efficacy of combined anti-retroviral/anti-leishmanial drug interactions (Costa et al. 2016) 
and indication of anti-leishmanial activity of HIV-protease inhibitors (van Griensven et al. 
2013).  However, there have been few studies where a rational approach to fully understand 
interactions between anti-leishmanial and anti-retroviral drugs and how this knowledge 
could be used to design more effective treatments. In contrast to tuberculosis and malaria 
where drug-drug interactions have been well characterised (see University of Liverpool 
University UK website www.hiv-druginteractions.org) there is limited analysis on anti-
leishmanial drugs.  
The collection of more PD data (from HCS screens) and PK data with the need to include 
specific compartments for tissues infected and uninfected, plus the over-riding need to 
integrate all to inform dosing of the novel drug in humans, has re-focused need for the 
application of computational, modelling and systems biology (van der Greef and McBurney, 
2005; Zhao and Iyengar, 2012).  Recent mathematical model of anti-malarials has focused 
on simulations of PK/PD to predict clinical activity of new compounds (Aljayyoussi et al., 
2016).  For leishmaniasis, a disease caused by a parasite that survives, multiplies and 
subverts the immune responses of the host macrophage (Kaye and Scott, 2011), the 
elements of immunity and immunopathology also have to be built into any predictive 
model. A computational Petri net model of L. donovani infection and granulomas in mouse 
liver (Moore et al., 2013; Albergante et al., 2013) illustrates another approach to disease 
simulation, an approach that is being further exploited to understand the relationship 
between the immune response and the activity and the PKs of anti-leishmanial drugs 
(www.crackit.org.uk/multiscale-model-minimise-animal-usage-leishmaniasis-drug-
development and www.leishsim.org) .  
 
CL, skin and topical formulations 
Considering the variety of clinical manifestations and the impact of cutaneous leishmaniasis, 
there is a notable absence of drugs and treatments that are clinically effective (Gonzalez et 
al., 2008; 2009); this is an area of research neglect.  This does not only apply to the classical 
forms of CL; there is also a need for improved treatments offering shorter courses, and less 
toxic drugs for post kala-azar dermal leishmaniasis (PKDL), as cases are infective to sandflies 
(Hirve et al., 2016) and PKDL patients act as a human reservoir for transmission and as such 
ARE a threat to elimination and control programmes.  
 
Most research on CL has been focussed on immunological responses to CL in mice and 
humans (Kaye, Scott, 2011; Scott, Novais 2016), leading to paradigms on T-cell responses, 
which in conjunction with developments in knowledge on skin immunity and inflammation 
(see Pasparakis et al. 2014) has provided some new understanding of the pathogenesis of 
CL. There have been several studies over the past decade showing how this understanding 
of skin immune response can be exploited for treatment, with a good example being the use 
of imiquimod in mice and humans (Buates et al., 1999; Cesar Miranda-Verastegui, M. et al., 
2009). More recently other approaches to treatment have resulted from long term human 
CL research in South America. Novais et al (2017) showed that NLRP3 inflammasome is 
activated by CD8+ T cell-mediated cytotoxicity and drives disease progression. This led to 
experimental studies in mice using a number of small molecule inhibitors of the 
inflammasome, for example, MCC950 and the diabetes drug glyburide. They showed that 
treatment with compounds that inhibit NLRP3 inflammasome activation, MCC950 or 
glyburide, failed to develop the severe disease seen in untreated mice.  
 
Apart from the immunotherapy approaches, the design and delivery of small molecules 
after oral administration to the skin has to be considered in the context of vascularisation 
(drug gradient and distance between blood vessel and site), an interstitial fluid 
compartment, the impact of inflammation on drug accumulation and extra-vasation, blood 
flow rate (slow) and local oxygen tension (low). Improved understanding of 
pharmacokinetics of anti-leishmanial drugs in the skin has come from clinical studies where 
Dorlo and colleagues provided data on both PK and PD in human CL (L. major) patients 
treated with miltefosine (Dorlo et al., 2008) although establishing the full relationship 
between exposure and response has yet to be determined.  We are now also beginning to 
understand how local inflammation at the CL site of infection can lead to specific 
accumulation of some drugs, for example liposomal amphotericin B, to improve cure 
(Wijnant et al., 2017b). 
 
A critical decision in the development pathway for CL treatment is whether to choose 
systemic or topical administration. Topical formulations have been used for the treatment 
of CL since the 1920s when stibosan (an early pentavalent antimonial) ointment was used to 
treat “oriental sore”. We have come a long way since 1935 when the use of an ointment 
consisting of “1 part pulverised vegetable charcoal and 9 parts of concentrated sulphuric 
acid” was described. However, the full exploitation of pharmaceutics and knowledge of skin, 
from utilisation of knowledge of skin physiology and PB PK models, alteration of vasculature, 
role of protein binding and other factors (Jepps et al. 2013), including lymphatic flow to 
deeper layers (Dancik et al. 2011), are only now being applied to the development of new 
treatments for CL.  The renaissance in the topical approach was led by El-On et al. (1984) 
with paromomycin, using an irritant and transdermal enhancing agent (methyl 
benzethonium chloride) to increase drug permeation by pore formation, the basis for the 
product Leishcutan ®(Teva, Israel).  Another formulation of topical paromomycin, containing 
15% paromomycin–0.5% gentamicin and several excipients (called WR 279,396) with known 
absorption and skin PK (Ravis et al. 2013) when applied with an occlusion, has successfully 
completed phase 3 trials (Ben Salah et al. 2013).  
Focus on potency, permeation, and distribution (Jepps et al. 2013) is important for both 
formulation design and the selection of appropriate compounds with both high potency 
and, through their chemical properties, dermal distribution.  As part of our strategy, we : (i) 
identify novel compounds that work against a panel of clinical isolates of the 15 species, as 
Leishmania species that cause CL vary significantly in their drug susceptibility (Escobar et 
al.,2002; Croft et al. 2006), (ii) select active compounds with appropriate medicinal 
chemistry, toxicity and ADME (absorption, distribution, metabolism, excretion) properties, 
(iii) test in mouse models of infection (oral and systemic administration), (iv) optimise for 
compound structure and formulations in relation to skin distribution, (v) decide whether 
topical administration is appropriate and further optimise the formulations using both 
mouse and human skin in permeation studies, and (vi) ensure that treatment is effective 
against early stage infections with intact skin (prior to ulceration) as the aim to develop a 
treatment effective before the patient has developed into a large disfiguring ulcer.  
When considering the pharmacokinetics of drugs for CL, it is important to remember that 
the Leishmania are in macrophages in the skin dermis, and that the infection is not 
superficial like many bacterial or fungal infections. Within the dermis at the site of infection, 
there is well characterised inflammation and and granuloma development (Scott, Novais, 
2016) and amastigotes in macrophages. This is found in both the nodule that precedes 
ulceration or later in the dermal rim around the ulcer. The aim for systemic formulation is 
penetration from the vasculature via the interstitial fluid and distribution to the 
inflammatory site of infection. However, for a topical formulation the aims are permeation 
of the skin barriers and then distribution to the site of infection. In both cases exposure 
following distribution and residence of the compound at the site of infection has to be 
optimised. Some of the practices of pharmaceutical scientists working on skin for cosmetics 
and other purposes have been adopted for CL studies over the past decade. Using 
methodologies like the Franz cell, it is possible to measure the rate of diffusion of anti-
leishmanial drugs across skin (of animal models and humans) alone and in different 
formulations, as shown for buparvaquone where the most effective topical formulation in 
vivo proved to be the one that crossed the skin most slowly in the Franz cell model (Garnier 
et al. 2007a,b). Recently this work has been extended to include Leishmania infected skin. 
Permeation markers, for example caffeine and ibuprofen, as well as some standard anti-
leishmanial drugs have been shown to have different in vitro permeation properties through 
normal mouse skin, compared with mouse skin removed from a nodule of infection (Van 
Boxclaer et al. 2016a). Drugs permeate significantly faster through skin taken from the site 
of infection, possibly due to oedema and the different immunological profile at this site of 
inflammation. As more extensive exposure in the dermis is critical to formulation design, the 
permeation properties of formulation excipients alone and together need to be explored.  A 
re-examination of topical formulations of the anti-leishmanial drug miltefosine, using in 
vitro and in vivo models already mentioned, and a range of formulations in which the 
partition of miltefosine was characterised, was unable to identify a formulation with good 
permeation and efficacy (Van Bocxlaer et al. 2016b).  
 
Conclusions for Leishmaniasis drug R & D  
There have been several reviews that represent the drug R & D process as a linear diagram 
from discovery to clinical trial. However, drug R & D is a multi-disciplinary iterative process 
with many decision points, and the involvement of several teams across disciplines (Baxter 
et al. (2013).  The parasitologist has key roles within this complex picture and an awareness 
of the comprehensive list of detailed information that s/he should aim to provide as part of 
a drug research team – ranging from work on enzyme targets to pharmacokinetics. Although 
the concept of the “minimum information about a bioactive entity (MIABE)” (Orchard et al., 
2011) was established to provide guidance for what and how results should be reported, 
their review also provides a fundamental list of research information that needs to be 
gleaned from studies. In the specific area of leishmaniasis and Leishmania, where there are 
a large variety of assays and models involving different species, strains and stages of the 
Leishmania parasite, different host cells and different mammalian hosts, it is hardly 
surprising that there can be significant differences in data obtained between laboratories 
resulting in reports of irreproducibility of compound activities. In addition to basic precepts, 
such inclusion of controls, Figure 4 is an attempt to summarise the main PD and PK related 
factors that must be considered when collecting data during drug discovery and early pre-
clinical studies for a novel anti-leishmanial compound.  Although there are benefits for 
standardisation, a process necessary when determining drug sensitivity of clinical isolates 
(Hendrickx et al. 2017), it is hardly feasible in the drug R & D process. But it is feasible for all 
those concerned to provide the levels of information sought and provided (Orchard et al. 
2011) so that data can be interpreted by all those interested in playing a role in the 
development of the next drug and treatment for leishmaniasis.  
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